
Opinion|Videos|June 24, 2024
Selecting Optimal Treatment in BCG-Unresponsive NMIBC
A panel of experts provide clinical insights on factors that inform how they select treatments for patients with BCG-unresponsive non–muscle invasive bladder cancer.
Advertisement
Episodes in this series

Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Choosing salvage therapy after prostate cancer focal ablation
2
Gemcitabine intravesical system delivers high 12-month DFS in papillary-only NMIBC
3
SYNC-T demonstrates high bone metastasis resolution in phase 1 cohort
4
CORE-008: Cretostimogene achieves high CR rate in high-risk NMIBC
5



















